Latest filings (excl ownership)
D
$240.00 mm in equity, sold $240.00 mm, 7 investors
3 May 24
8-K
Other Events
3 May 24
8-K/A
Entry into a Material Definitive Agreement
29 Apr 24
8-K
Entry into a Material Definitive Agreement
24 Apr 24
8-K
Entry into a Material Definitive Agreement
24 Apr 24
S-8
Registration of securities for employees
22 Apr 24
8-K
Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
22 Apr 24
10-K
2023 FY
Annual report
22 Apr 24
8-K
Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review
16 Apr 24
8-K
Submission of Matters to a Vote of Security Holders
5 Apr 24
NT 10-K
Notice of late annual filing
1 Apr 24
DEF 14A
Definitive proxy
4 Mar 24
PRE 14A
Preliminary proxy
23 Feb 24
8-K
Other Events
9 Feb 24
8-K
Other Events
22 Dec 23
8-K
Other Events
17 Nov 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
16 Nov 23
8-K
Cidara Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results
2 Nov 23
10-Q
2023 Q3
Quarterly report
2 Nov 23
8-K
Cidara Therapeutics and Mundipharma receive positive CHMP opinion for rezafungin for the treatment of Invasive Candidiasis in adults1
13 Oct 23
8-K
Other Events
21 Sep 23
8-K
Cidara Therapeutics Announces Janssen’s Election to Proceed Under its License Agreement Relating to Novel Drug-Fc Conjugates Targeting Influenza
6 Sep 23
8-K
Cidara Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results
3 Aug 23
10-Q
2023 Q2
Quarterly report
3 Aug 23
UPLOAD
Letter from SEC
24 Jul 23
CORRESP
Correspondence with SEC
7 Jul 23
UPLOAD
Letter from SEC
26 Jun 23
8-K
Submission of Matters to a Vote of Security Holders
23 Jun 23
CORRESP
Correspondence with SEC
31 May 23
8-K
Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results
11 May 23
10-Q
2023 Q1
Quarterly report
11 May 23
UPLOAD
Letter from SEC
28 Apr 23
ARS
2022 FY
Annual report to shareholders
27 Apr 23
DEFA14A
Additional proxy soliciting materials
27 Apr 23
DEF 14A
Definitive proxy
27 Apr 23
S-8
Registration of securities for employees
23 Mar 23
8-K
Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results
23 Mar 23
10-K
2022 FY
Annual report
23 Mar 23
8-K
Other Events
6 Mar 23
424B5
Prospectus supplement for primary offering
6 Mar 23
Latest ownership filings
4
Rajeev M. Shah
30 Apr 24
3
Rajeev M. Shah
30 Apr 24
4
Ryan Spencer
30 Apr 24
3
Ryan Spencer
30 Apr 24
4
James Merson
30 Apr 24
3
James Merson
30 Apr 24
4
Laura Tadvalkar
30 Apr 24
3
Laura Tadvalkar
30 Apr 24
4
Shane Ward
20 Mar 24
4
Preetam Shah
20 Mar 24
4
Leslie Tari
20 Mar 24
4
Taylor Sandison
20 Mar 24
4
Jeffrey Stein
20 Mar 24
4
Jeffrey Stein
12 Mar 24
4
Leslie Tari
12 Mar 24
4
Taylor Sandison
12 Mar 24
4
Shane Ward
12 Mar 24
4
Preetam Shah
12 Mar 24
SC 13G/A
Nantahala Capital Management, LLC
14 Feb 24
SC 13G/A
BIOTECHNOLOGY VALUE FUND L P
14 Feb 24
SC 13G/A
Point72 Asset Management, L.P.
14 Feb 24
4
Leslie Tari
13 Sep 23
4
Taylor Sandison
13 Sep 23
4
Leslie Tari
14 Aug 23
4
Jeffrey Stein
8 Aug 23
4
Chrysa Mineo
23 Jun 23
4
Carin Canale-Theakston
23 Jun 23
4
Theodore R Schroeder
23 Jun 23
4
Timothy R Franson
23 Jun 23
4
DANIEL D BURGESS
23 Jun 23
4
Bonnie L Bassler
23 Jun 23
4
David L Gollaher
23 Jun 23
4
Shane Ward
29 Mar 23
4
Jeffrey Stein
29 Mar 23
4
Taylor Sandison
29 Mar 23
4
Leslie Tari
29 Mar 23
4
Preetam Shah
29 Mar 23
4
Jeffrey Stein
27 Mar 23
4
Shane Ward
13 Mar 23
4
Leslie Tari
13 Mar 23